FibroGen Inc (FGEN)
0.3643
+0.03
(+10.19%)
USD |
NASDAQ |
Nov 14, 12:28
FibroGen Free Cash Flow: -202.99M for June 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2024 | -202.99M |
| March 31, 2024 | -274.68M |
| December 31, 2023 | -317.54M |
| September 30, 2023 | -351.81M |
| June 30, 2023 | -319.34M |
| March 31, 2023 | -241.74M |
| December 31, 2022 | -184.67M |
| September 30, 2022 | -188.18M |
| June 30, 2022 | -117.76M |
| March 31, 2022 | -112.03M |
| December 31, 2021 | -112.42M |
| September 30, 2021 | -65.68M |
| June 30, 2021 | -85.13M |
| March 31, 2021 | 92.05M |
| December 31, 2020 | 77.61M |
| September 30, 2020 | 40.43M |
| June 30, 2020 | 12.90M |
| March 31, 2020 | -166.41M |
| December 31, 2019 | -84.47M |
| September 30, 2019 | -58.30M |
| Date | Value |
|---|---|
| June 30, 2019 | -21.91M |
| March 31, 2019 | -28.37M |
| December 31, 2018 | -84.16M |
| September 30, 2018 | -68.22M |
| June 30, 2018 | -97.14M |
| March 31, 2018 | -81.04M |
| December 31, 2017 | -75.01M |
| September 30, 2017 | -89.01M |
| June 30, 2017 | -69.05M |
| March 31, 2017 | -3.759M |
| December 31, 2016 | 5.856M |
| September 30, 2016 | -15.06M |
| June 30, 2016 | -52.02M |
| March 31, 2016 | 3.934M |
| December 31, 2015 | -20.55M |
| September 30, 2015 | -7.277M |
| June 30, 2015 | -1.122M |
| March 31, 2015 | -10.49M |
| December 31, 2014 | 14.30M |
Free Cash Flow Range, Past 5 Years
-351.81M
Minimum
Sep 2023
92.05M
Maximum
Mar 2021
-136.94M
Average
-117.76M
Median
Jun 2022
Free Cash Flow Benchmarks
| Biomarin Pharmaceutical Inc | 300.88M |
| Arbutus Biopharma Corp | -71.92M |
| GlycoMimetics Inc | -35.72M |
| Cidara Therapeutics Inc | -125.11M |
| Cue Biopharma Inc | -38.60M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -39.87M |
| Cash from Investing (Quarterly) | 72.24M |
| Cash from Financing (Quarterly) | 0.032M |
| Free Cash Flow Per Share (Quarterly) | -0.3995 |
| Free Cash Flow to Equity (Quarterly) | -40.15M |
| Free Cash Flow to Firm (Quarterly) | -33.91M |
| Free Cash Flow Yield | -563.5% |